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virus–associated granule cell neuronopathy (JCV GCN) in a natalizumab-treated patient with
multiple sclerosis (MS) who developed immune reconstitution inflammatory syndrome (IRIS) after
natalizumab withdrawal.
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Results: This patient presented with worsening cerebellar symptoms and progressive cerebellar

ABSTRACT

Objective: To describe the clinical, neuroimaging, immunologic, and virologic characteristics of JC

Methods: We obtained longitudinal clinical data as well as MRI and proton magnetic resonance
spectroscopy from this patient with MS. We measured JCV-specific cellular immune response
in his peripheral blood by intracellular cytokine staining and sequenced a fragment of JCV VP1
capsid gene detected in his CSF. We contrast our findings with the first recently reported case.
atrophy without new MS lesions on MRI after 63 months of natalizumab monotherapy. JCV
DNA was detected in his CSF by PCR and harbored novel GCN-type mutations in the VP1 gene.
He developed IRIS upon discontinuation of natalizumab and plasma exchange, which manifested
itself by a worsening of clinical symptoms and contrast enhancement in the cerebellum on MRI.
Treatment with corticosteroids resulted in resolution of IRIS, as demonstrated by proton magnetic resonance spectroscopy. The patient had a strong JCV-specific T-cell response in his
peripheral blood and remains alive after 15 months from onset of symptoms, although with significant disability. He did not have MS relapse on glatiramer acetate.

Conclusions: JCV GCN should be considered in patients on natalizumab presenting with progressive cerebellar symptoms and cerebellar atrophy, and is associated with mutations in the
JCV VP1 gene. Natalizumab withdrawal may be complicated by JCV GCN IRIS, and require
treatment with corticosteroids. Neurology® 2014;83:727–732
GLOSSARY
aa 5 amino acid; bp 5 base pair; GCN 5 granule cell neuronopathy; 1H-MRS 5 proton magnetic resonance spectroscopy;
IRIS 5 immune reconstitution inflammatory syndrome; JCV 5 JC virus; MS 5 multiple sclerosis; PLEX 5 plasma exchange;
PML 5 progressive multifocal leukoencephalopathy; RR 5 regulatory region.

JC virus (JCV) causes lytic infection of oligodendrocytes, leading to demyelinating disease of the
brain called progressive multifocal leukoencephalopathy (PML). In addition, JCV may infect
cerebellar granule cell neurons resulting in JCV granule cell neuronopathy (GCN).1
JCV GCN, described in patients with HIV, sarcoidosis, and CD40 ligand deficiency, is associated with mutations in the C terminus of the JCV VP1 gene, coding for the major capsid
protein.2,3 Natalizumab, which prevents egress of lymphocytes from the bloodstream, is used for
treatment of multiple sclerosis (MS) and Crohn disease. As of March 6, 2014, 448 patients with
MS and 2 patients with Crohn disease treated with natalizumab have developed PML worldwide.4 Recently, JCV GCN was also described in a patient with MS presenting with cerebellar
symptoms and atrophy after 52 months of natalizumab monotherapy.5 This patient developed
immune reconstitution inflammatory syndrome (IRIS) after natalizumab withdrawal, characterized by inflammatory infiltrates in the cerebellar parenchyma, but did not have contrast
enhancement on MRI. Whether JCV GCN caused by natalizumab is also associated with
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JCV VP1 mutations is unknown. We present
here the second case of natalizumab-associated
JCV GCN. Sequential MRI studies, results of
proton magnetic resonance spectroscopy (1HMRS), and testing of JCV-specific immune
response highlight differences with the initial
case. Sequence analysis revealed novel GCNtype mutations in the VP1 gene.
A 32-year-old man with MS for 12 years was
switched to natalizumab from interferon b-1b, when
he experienced repeated relapses. He was JCVseropositive and had received 63 infusions of
natalizumab monotherapy when he presented with
changes in his handwriting, speech, and gait. MRI,
done 2 weeks after onset of symptoms (figure 1, A
and B), showed no new lesions. He was treated with
oral corticosteroids for suspected MS exacerbation, but
continued to have progressive cerebellar symptoms.
CSF analysis 3 months after onset of symptoms
showed 2 white blood cells/mm3 with a protein
concentration of 70 mg/dL. JCV PCR was positive,
confirming the diagnosis of JCV GCN. Natalizumab
was discontinued and he received plasma exchange
(PLEX) for 5 days, followed by mirtazapine 15 mg/d
orally. IV methylprednisolone was given for 5 days to
prevent IRIS. MRI showed progressive cerebellar
CASE

Figure 1

atrophy without any confluent white matter lesions
(figure 1, C and D). Approximately 4 weeks after
PLEX, he developed vertigo, headaches, and
dysphonia, and CSF examination showed 71 white
blood cells/mm3 with 95% lymphocytes and protein
of 136 mg/dL. CSF JC viral load was 16,489 copies/
mL. There were hyperintense lesions in the pons and
cerebellar peduncles on fluid-attenuated inversion
recovery MRIs, as well as contrast enhancement
within the cerebellum (figure 1, E and F), suggestive
of IRIS. He was treated with 7 days of IV
methylprednisolone and was started on maraviroc
given a putative benefit in IRIS, while remaining
on mirtazapine.
Intracellular cytokine staining, performed as
described previously, showed a robust cellular
immune response mediated by JCV-specific CD41
and CD81 T cells producing interferon g (figure
2A).6 Molecular analysis of CSF JCV strains, performed as previously described, revealed mutations
in the C terminus of the VP1 gene, consistent with
GCN-type JCV strains (figure 2B).3 A total of 3 new
GCN-type JCV strains were found: JCVGCN1b
(16.7% clones) has identical 10–base pair (bp) deletion as reported for JCVGCN1 in a different backbone;
JCVGCN6 (66.7% clones) has a novel 3-bp deletion
between nt 2,497 and 2,499; and JCVGCN7 (16.7%
clones) has a novel 18-bp deletion between nt 2,494

MRIs of cerebellum and brainstem demonstrate progressive cerebellar atrophy and immune
reconstitution inflammatory syndrome

(A) FLAIR and (B) precontrast T1 images are taken within 2 weeks of symptoms onset. (A) Few hyperintense lesions in the
cerebellar peduncles that had been stable for many years. (B) Baseline size of the cerebellum. (C) FLAIR and (D) precontrast
T1 images done 4 months after initial presentation and a week after positive CSF JC virus PCR show marked cerebellar
atrophy compared with the scan done 3.5 months before (B) without any new hyperintense lesions in the cerebellar
peduncles. FLAIR (E) and postcontrast T1 (F) images done 4 weeks after plasma exchange treatment identify new diffuse
hyperintensities in the cerebellum as well as contrast enhancement, suggestive of immune reconstitution inflammatory syndrome. FLAIR 5 fluid-attenuated inversion recovery; PLEX 5 plasma exchange.
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Figure 2

Strong T-cell response to JCV and mutations in C terminus of JCV VP1 gene

(A) Strong interferon (IFN) g response is observed in CD41 and CD81 T cells from peripheral blood after stimulation with JCV
peptides 7 months after initial presentation. The percentages of IFNg-expressing CD41 T cells (upper row) and CD81 T cells
(lower row) are indicated in each dot plot. (B) Alignment of DNA and amino acid (aa) sequence of VP1 C termini of all known
GCN-type JCV and prototype JCV Mad-1. The CSF of our patient contains GCN1b, GCN6, and GCN7 subtypes. GCN 5
granule cell neuronopathy; JCV 5 JC virus; MS 5 multiple sclerosis; NHL 5 non-Hodgkin lymphoma; NTZ 5 natalizumab.
Modified from Dang and Koralnik,2 © 2013 American Neurological Association, with permission.

and 2,511. At the protein level, JCVGCN1b has identical amino acid (aa) sequence as JCVGCN1, JCVGCN6
has 1 aa deletion at position 344, and JCVGCN7 has a
truncated new end at aa 341. Notably, JCV DNA,

tested 3 months after PLEX, was not detected in the
plasma, peripheral blood mononuclear cells, or urine
of this patient. The sequence of JCV hypervariable
regulatory region (RR) amplified from the CSF of our
Neurology 83

August 19, 2014

729

Figure 3

Resolution of immune reconstitution inflammatory syndrome and
spread of white matter lesions on MRI 11 months after initial
presentation

(A) T1 precontrast image demonstrates significant atrophy of the cerebellar vermis. (B)
FLAIR image showing worsening of the diffuse white matter hyperintensities in the brainstem (arrow). (C) T1 postcontrast image shows resolution of the cerebellar enhancement
noted previously. FLAIR 5 fluid-attenuated inversion recovery.

patient was identical to that obtained from the initial
case of JCV GCN, showing an archetype-like RR.7
The patient’s neurologic function stabilized concomitant with negative repeat JCV CSF PCR 4 months
after PLEX. MRI and 1H-MRS obtained 8 months after
onset of symptoms showed near resolution of cerebellar
enhancement and a lipid 1/creatine ratio ,1.0 in cerebellum consistent with subsiding IRIS.8
Eleven months after initial presentation, ataxia,
nystagmus, and dysarthria persisted. MRI at that time
showed cerebellar atrophy, especially in the vermis
(figure 3A), along with progression of fluidattenuated inversion recovery hyperintensities in the
pons and cerebellar peduncles (figure 3B). There
was no further enhancement on postcontrast images
(figure 3C). Spasticity from his cervical MS lesions
and the cerebellar ataxia restrict him to a wheelchair
for most of the time. Maraviroc was discontinued,
and his MS has remained stable on glatiramer acetate
15 months after JCV GCN onset.
This is the second case of JCV GCN
in a natalizumab-treated patient with MS. Both
DISCUSSION

Table

patients received more than 50 doses of
natalizumab monotherapy and had progressive
cerebellar symptoms without white matter changes
suggestive of PML on initial MRI.5 They were both
treated with PLEX and survived with significant
morbidity.
However, our patient differs from the one reported by Schippling et al.5 in various aspects (table).
Our patient had an MRI 1 month after his initial
presentation, which did not identify any cerebellar
atrophy, whereas it was already evident in the other
case on the first MRI 4 months after symptom onset.
Our patient also developed extensive white matter
lesions in the pons and cerebellar peduncles 9 months
after initial presentation, despite a negative JCV PCR
in CSF. The follow-up in their patient lasted 5
months, during which no white matter lesions were
observed.
It is therefore possible that JCV initially infected
granule cell neurons, causing cerebellar atrophy,
and then spread in the cerebellar and pontine white
matter. Nevertheless, the stabilization of the lesions
and extended survival of our patient are remarkable,
commensurate with a strong cellular immune response
to JCV, consistent with our observations in PML.6
The stronger CD4 response, measured after IRIS
onset, supports the role of CD41 T cells in IRIS in
natalizumab-treated patients with MS, as it has been
shown in the setting of PML.9
Notably, our patient developed contrast enhancement in the cerebellum on MRI in association with
IRIS, contrary to the case of Schippling et al., where
IRIS was diagnosed only by identification of T-cell
infiltrates on cerebellar biopsy. In both cases, IRIS
was triggered by the return of lymphocytes in a cerebellum heavily infected by JCV, causing local inflammation. Whether extension of lesions and clinical
worsening were caused by a prolonged IRIS requiring
additional corticosteroids or the natural progression
of JCV GCN where corticosteroids would be

Comparison of 2 patients with natalizumab-associated JCV GCN

JCV GCN

Present case

Schippling et al.5

Length of natalizumab monotherapy

63 mo

52 mo

Cerebellar atrophy on first MRI after symptoms onset

Absent at 1 mo

Present at 4 mo

Contrast enhancement on MRI during IRIS

1

2

Cerebellar infiltrate of T lymphocytes during IRIS

NA

1

Strong JCV-specific T-cell response in blood and extended survival

1

NA

1

NA

1

H-MRS suggesting subsiding IRIS

Identification of GCN-type JCV mutations in CSF

1

NA

Extension of lesions in cerebellar and pontine white matter

1

2

Abbreviations: GCN 5 granule cell neuronopathy; 1H-MRS 5 proton magnetic resonance spectroscopy; IRIS 5 immune
reconstitution inflammatory syndrome; JCV 5 JC virus; NA 5 not applicable.
730

Neurology 83

August 19, 2014

contraindicated created a difficult clinical conundrum
in our case. We therefore used the algorithm recently
delineated in PML, showing low lipid 1/creatine ratio
on 1H-MRS and subsiding contrast enhancement in
the lesions. In PML, this constellation corresponds to
a probability of IRIS of only 13%.8 Indeed, high lipid
peaks are thought to be a marker for T-cell infiltration
and have been reported in various inflammatory conditions such as MS, acute disseminated encephalomyelitis, and PML-IRIS.10,11 Whether this algorithm can
be validated in JCV GCN as well will require further
study.
Maraviroc is an antiretroviral medication that
blocks binding of HIV to the CCR5 receptor. It is
thought to have immunomodulating properties by
blocking the binding of natural CCR5 ligands and
has been used in HIV1 and HIV2 patients with
PML-IRIS.12,13 Our experience however, does not
suggest that this medication is indicated in HIV2
PML-IRIS cases.
Finally, we found for the first time that JCV GCN
triggered by natalizumab in the context of MS is also
associated with mutations in the VP1 gene coding for
the major capsid protein. We identified 2 novel mutations that help substantiate the association between
GCN-type JCV and the clinical syndrome of JCV
GCN. The exact mechanism of how these mutations
originate and result in tropism to the granule cells is
unclear. In vitro modeling revealed that the initial
GCN1 mutant, also present in our patient, was replication competent and stable, but had a disadvantage
for growth in glial cells compared with undeleted
JCV.3 The fact that JCV RR in our case also had
an RR identical to the GCN1 isolate characterized
10 years ago is also significant, because the RR found
in PML is usually hypervariable. Moreover, JCV
could not be detected in the blood, peripheral
blood mononuclear cells, or urine of this patient,
suggesting that the JCV mutation most likely originated in the CNS.
The description in close succession of 2 cases of
natalizumab-associated JCV GCN highlights the
importance of recognizing this syndrome in MS
and, potentially, in patients with Crohn disease.
Initial MRI, if done within the first month of
symptoms, may not identify any cerebellar atrophy
and only a high degree of suspicion can lead to CSF
testing. However, the sensitivity of CSF JCV PCR
for diagnosis of JCV GCN is unknown, and definitive proof may require cerebellar biopsy. Identification of GCN-type mutations is a key feature of
differentiation with PML. In the absence of a definite
treatment against JCV, early withdrawal of natalizumab followed by PLEX constitutes the only hope
for the immune system to contain JCV GCN and
avoid irreversible cerebellar damage. IRIS should be

expected as a complication of this treatment, and timing of corticosteroid administration may be guided by
1
H-MRS.
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